Navigation Links
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:9/25/2007

- Study Will Assess Drug's Benefit, Alone and With Lipitor(R), in Overweight or Obese Patients with High Cholesterol and Triglycerides -

HAYWARD, Calif., Sept. 25 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug's effect on dyslipidemia, insulin-resistance and obesity.

Preclinical and clinical testing of MBX-8025 indicates that the drug has the potential to improve a number of lipid parameters that are abnormal in different types of dyslipidemia, including high LDL (or "bad") cholesterol, high Apo B-100 (the atherogenic lipoprotein), low HDL (or "good") cholesterol and high triglycerides (fats). In addition, MBX-8025 has been shown to exhibit positive effects on insulin sensitization and body weight. The randomized, double-blind Phase 2 trial will assess the potential of the drug alone and in combination with Lipitor(R) (atorvastatin).

"Although high LDL levels are widely treated as a risk factor for heart disease, many patients are unable to reach increasingly low LDL targets on a statin alone. Additionally, existing drugs do a poor job of targeting the entire range of different lipid disorders that contribute to cardiac risk. We believe this trial will provide us crucial evidence in assessing the ability of MBX-8025 to lower Apo B-100, LDL and triglyceride levels, as well as raise HDL levels, improve insulin sensitivity and reduce body weight," said David B. Karpf, M.D., the chief medical officer of Metabolex. "In addition, we are testing the drug in conjunction with Lipitor, the best-selling lipid-lowering drug in the world, to determine whether combination therapy with a statin will be well tolerated and lead to even better results."

The study will enroll 180 overweight or obese non-diabetic patients and assess two different doses of MBX-8025, given over an 8-week treatment period, both alone and in combination with Lipitor(R). The primary endpoint is the reduction in Apo B-100 compared with placebo. Secondary endpoints include measurements of the effect of treatment on LDL, HDL, triglycerides and body weight and composition. Metabolic parameters, including glucose and insulin levels, will also be assessed.

MBX-8025 regulates fatty acid degradation, lipid storage/transport and insulin sensitivity. Metabolex has in-licensed the patents and the exclusive development and commercialization rights to MBX-8025 from Janssen Pharmaceutica NV, a Johnson & Johnson company.

About Metabolex

Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has three clinical-stage compounds: MBX-102/JNJ 39659100, in Phase 2/3 testing; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, now in Phase 2. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100 and MBX-2044. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... LOVELAND, Colo. , Jan. 16, 2017  Northern ... , is bringing advanced laser treatments to ... specialty clinic focuses solely on the removal of unwanted ... and fading for tattoo cover-ups. "Tattoos are ... out the way we hope they would," said ...
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
(Date:1/16/2017)... -- Transparency Market Research states that the leading ... a huge share of 43% in 2015. Apple Inc., F.Hoffmann-La ... overall market, grabbing the undivided attention of buyers with their ... strong product portfolio is expected to keep these companies in ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... ... , ... Wondering where to go this Valentine's Day? Well, there is a ... romantic, lobster feast in the comfort of your own home. Lobster Gram is introducing ... be featured until February 15th, 2017. , Romantic Dinner one is Lobster Gram's ...
(Date:1/14/2017)... ... January 13, 2017 , ... ... Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type 2 ... notes that the many health and wellness benefits linked to a Mediterranean diet ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in Madrid ... expertly designed to meet the educational needs of European oncology clinicians and researchers who ... Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized by ...
Breaking Medicine News(10 mins):